AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05681078 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Matter of Balance: Managing Concerns about Falls
Description: A Matter of Balance is an evidence-based program targeting physical activity and fall prevention for adults 60 years of age and older. This program incorporates active learning discussions and activities along with exercise training to reduce the fear of falling, improve fall efficacy and management, and increase physical activity levels in older adults.
Study NCT06494644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6793
Description: Participants will receive single dose of AZD6793 on Day 1 in Period 1 and on Day 8 in combination with itraconazole in Period 3.
Study NCT06494644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Participants will receive 2 doses of itraconazole on Day 4 and single dose from Day 5 to Day 7 in Period 2. On Day 8 participants will receive single dose of itraconazole combined with AZD6793 and then single dose of itraconazole from Day 9 to Day 10 in Period 3.
Study NCT06494644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6793+ Itraconazole
Description: Participants will receive a combined dose of AZD6793 and itraconazole on Day 8 in Period 3.
Study NCT05074303 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine
Description: All subjects will receive the influenza vaccine.
Study NCT05074303 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Influenza Vaccine
Description: All subjects will receive the influenza vaccine.
Study NCT05074303 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-glucan
Description: 2 - 250 mg capsules/day of beta-glucan derived from Baker's yeast
Study NCT05074303 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 - 250 mg capsules/day of cellulose
Study NCT05134883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF
Description: A PNF stretching protocol will be performed with each participant assuming a long sitting position on a plinth with the knee maintained as extended as possible. At this moment, the participant will be asked to perform a maximum isometric hamstring muscle contraction for 5 seconds followed by 5 seconds of relaxation and 20 seconds of stretching. The therapist will show the participant how to maintain this isometric contraction with the flexion of the hip and ankle. Each participant will undergo 4 repetitions of PNF stretching (30 seconds/rep).
Study NCT05134883 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMR
Description: For the application of self-myofascial release, the subjects will assume a long sitting position on a firm and even surface by placing the arms backward and transferring their body weight to their palms. The roller foam, applied bilaterally, will be placed under the hamstrings and slowly moved back and forth from the ischial tuberosity to the popliteal fossa by applying pressure for 2 minutes.
Study NCT06519747 — intervention group
Intervention type: DEVICE
Intervention: Cardiac monitoring device
Description: Portable, up to 14 days of monitoring
Study NCT05780047 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mail-in Urine Test for EDCs
Description: Million Marker provides a mail-in urine test for Bisphenol A (BPA) and phthalates. Users take a comprehensive exposure survey (via the MM app), send back their samples, view their personalized reports with tailored product recommendations, make changes to reduce their exposures, and retest to monitor their progress. Participants will also fill out surveys to assess changes in their environmental health literacy, readiness to change, and analyses of lifestyle behaviors and product use.
Study NCT04739423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clenbuterol (CST-103), nadolol (CST-107), matching placebo
Description: clenbuterol (CST-103) and matching placebo orange capsules; nadolol (CST-107) and matching placebo white capsules
Study NCT05307562 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interval training + analytical strength
Description: Patients will receive a training program
Study NCT05307562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval training + analytical strength and IMT
Description: Patients will receive a training program + IMT
Study NCT04499482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: Soy-fiber containing food
Study NCT04305730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of a pedometer following surgery
Description: Subjects in the study group will receive a pedometer with graduated step count goals as discussed in arm description.
Study NCT04305730 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Subjects in the control group will be counseled on the importance of ambulation during their pre-operative visit.
Study NCT01495715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idebenone
Study NCT01495715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT06096350 — intervention group
Intervention type: DEVICE
Intervention: robotic assisted intervention
Description: Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
Study NCT06096350 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: hematochemical analysis
Description: Blood samples of patients will be collected from patients in the early morning (7:30-9:00 a.m.) after an overnight fast at T0 and at T1. Sera samples will be separated by centrifugation (3,000 rpm, 10 min, and 4 °C), divided into 0.5 mL aliquots, and rapidly stored at -80 °C. Subjects' and reference samples were thawed just before the diagnostic test.
Study NCT06096350 — intervention group
Intervention type: DEVICE
Intervention: BIA, hand grip
Description: bioimpedentiometric analyses of muscular mass (T0 and T1), muscular force with hand grip
Study NCT06096350 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: nutritional assessment, MNA,
Description: nutritional status assessment will be performed by: body mass index measurements, (height and weight measurements at T0 and at T1); a Mini Nutritional Assessment survey will be administered to patients at admission; a food questionnaire will be administered to patients during from T0 to T1.
Study NCT06096350 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: stool sampling
Description: stool will be collected at T0 and at T1
Study NCT06096350 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: urine sampling
Description: the first morning urine will be collected at T0 and at T1
Study NCT05305638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Home-based physical activity programs are very important to strengthen the immune system, which is extremely important in the fight against COVID-19 infection, and to protect physical and mental health. In addition, since the pulmonary rehabilitation sessions carry a high risk of transmission, it is recommended that the program be carried out with applications such as single-session training, tele-rehabilitation or home program. Although the home pulmonary rehabilitation program is adapted to the individual, it generally includes positioning, mobilization, relaxation exercises, respiratory training, respiratory muscle exercises, upper and lower extremity exercises, walking, climbing stairs and cycling exercises. The general opinion is that telerehabilitation practices have many benefits such as increasing the quality of life and physical activity. In addition to these benefits, telerehabilitation applications come to the fore in the Covid-19 period with its complementary feature.
Study NCT05163990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcutaneous acupoint electrical stimulation
Description: The corresponding transcutaneous acupoint electrical stimulation is given to different groups before spinal anesthesia, which last from 10 minutes before anesthesia to 30 minutes after subarachnoid administration.
Study NCT05032352 — intervention group
Intervention type: DRUG
Intervention: Adjuvant
Description: Adjuvant treatment with a standard NSCLC platin-based doublet, 4 cycle (21-day) regimen of the investigator's choice (Arm 1) or other adjuvant therapy (Arm 1a) which can include combination of chemotherapy and targeted therapy, immunotherapy or other.
Study NCT05032352 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: All patients will be observed for progression free survival and overall survival to the end of study or death, whichever occurs first.
Study NCT06010563 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter pulmonary valve implantation (TPVI)
Description: A valve is implanted through a catheter (a narrow tube) and inserted through the femoral vein into the right atrium, right ventricle and pulmonary artery. After careful positioning, the valve is implanted by inflating a set of a balloons on the delivery catheter or self-expanding. After the catheter has been removed, the incision is closed with stitches, which are removed after the area has healed.
Study NCT06010563 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VenusP-ValveTM System
Description: VenusP-ValveTM System consists of two components:~1. Transcatheter Pulmonary Valve (TPV)~2. Delivery System (DS) including Delivery Catheter System (DCS) and Compression Loading System (CLS) The TPV consists of a self-expanding nitinol stent with a single layer tri-leaflet porcine pericardium tissue.~For the Delivery Catheter System (DCS) , the distal (deployment) end of the system features an atraumatic, radiopaque tip. A protective sheath (capsule) covers and maintains the TPV in a crimped position. The handle at the proximal end of the catheter is used to load and deploy the TPV.~The CLS compresses the TPV into the catheter, which including capture tube, valve protection tube, tip support tube, loading mandrels and crimper.
Study NCT06437366 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-Led Heart Math Training Program
Description: he nurse-led HeartMath training program consists of several key components designed to enhance resilience, sense of coherence, and emotional adjustment:~Heart-Focused Breathing Techniques: Patients are taught specific breathing techniques that help synchronize heart and brain activity, leading to a state of physiological coherence.~Emotional Regulation Skills: The training includes exercises that help individuals recognize and shift from negative to positive emotional states, thereby improving emotional stability and reducing stress.
Study NCT05444439 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: detection of vacuolating cytotoxin A (Vac A) and cytotoxin-associated gene A (Cag A) virulent H.Pylori genotypes by polymerase chain reaction amplification(PCR) in gastric biopsies :
Description: Extraction of DNA, using Wizard® Genomic DNA Purification Kit (Promega-USA), will be done following the manufacturer instructions. For detection of vacuolating cytotoxin A and cytotoxin-associated gene A gene, polymerase chain reaction amplification will be performed with a 9 minutes' initial denaturation at 94˚C, followed by 35 cycles of 1 minute at 94˚C, 45 seconds at 60˚C, and 45 seconds at 72˚C. Final extension will be performed for 5 minutes at 72˚C. For detection of vacuolating cytotoxin A (S1/S2, m1, m2), PCR will be performed with a 9 minutes' initial denaturation at 94˚C, followed by 35 cycles of 1 minute at 94˚C, 45 seconds at 56˚C, and 45 seconds at 72˚C. Final extension will be performed for 5 minutes at 72˚C. Amplified DNA will be analyzed by agarose gel electrophoresis. A positive sample will give bands at DNA fragment 138-bp for cytotoxin-associated gene A, at 259/286-bp for vacuolating cytotoxin A s1/s2, and 290-bp and 352-bp for m1 \& m2, respectively
Study NCT05444439 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Culture and sensitivity of endoscopic gastric biopsies:
Description: During endoscopy, three biopsies will be taken from antrum and/or corpus of and will be examined by rapid urease test also known as Campylobacter-like organism test (Kimberly-Clark,USA). Culture of the bacterium on Columbia agar plus 5-7% defibrinated horse or sheep blood and selective Dent supplement under microaerophilic condition at 37degree Celsius for 3-5days.
Study NCT05276947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: position with peanut ball
Description: The experimental group will be positioned with the peanut ball until the end of the active phase of labor.
Study NCT05444439 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Histopathological examination endoscopic gastric biopsies:
Description: Histological sections from the antrum and body regions will be stained with Giemsa stain. Giemsa stain working solution was prepared as follows: 40 ml Giemsa stock solution with 60 ml of distilled water. Giemsa stock solution will be prepared as follows: Giemsa powder 4 g, glycerol 250 ml and methanol 250 ml. Histological sections will be examined by a gastrointestinal pathologist to standardize the classification of gastritis. Histopathological classification will be recorded as following (acute gastritis, mild-moderate- severe chronic gastritis, Glandular atrophy or Intestinal metaplasia).
Study NCT05444439 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Upper endoscopy
Description: it will be done patient before start empirical therapy and multiple antrum and/or corpus biopsies will be taken . Patient will be fasting at least 8 hours.Upper and findings will be recorded in the report as presence of gastroesophageal reflux disease, diffuse or localised gastric and/or duodenal redness, mucosal swelling, atrophy of mucosa, nodularity, intestinal metaplasia, erosions or ulcers.
Study NCT05444439 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: empirical H.pylori regimens
Description: Start empirical antibiotics regimens patient triple therapy ((levofloxacin 400 mg once , amoxicillin 1000 mg twice for 2 weeks) and (Proton pump inhibitor twice for 1 month)). Follow up after 2 weeks after finishing regimen by Stool Ag in stool
Study NCT05444439 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: H.Pylori Ag in stool
Description: Any symptomatic patient is above 18 years old with H pylori infection patients diagnosed by positive H pylori Ag in stool will be included.~assessment of laboratory response, 2 weeks after finishing empirical therapy.
Study NCT06350539 — intervention group
Intervention type: OTHER
Intervention: Biological Sample Collection
Description: Excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).
Study NCT05255029 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POD T 49P implantation experimental
Description: The investigational lens will be implanted within the capsular bag after removal of the natural crystalline lens following phacoemulsification and alignment the toric axis of investigational lens to the intend axis which was calculated by the Toric calculator software. When enroll the test lenses into both eyes, the lens is implanted first to the eye with more advanced cataract. If both eyes have a similar degree of cataract, perform the surgery first for the right eye. The timing of surgery the investigational lens into the fellow eye will be determined after the investigator and the investigator (hereinafter referred to as the investigator) have confirmed the safety of the previously operated eye.
Study NCT05928572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CGM initiation approach
Description: Use of a nutrition-focused approach versus a self-directed approach during CGM initiation
Study NCT05928572 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CGM initiation approach
Description: Use of a nutrition-focused approach versus a self-directed approach during CGM initiation
Study NCT05392751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EA-2353
Description: EA-2353 Ophthalmic Suspension
Study NCT05152628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus granules
Description: Oral
Study NCT04986189 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Low dose CT thorax
Description: A low dose CT scan of the thorax to screen for lung cancer
Study NCT05566236 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: board game
Description: A board game was designed based on situated learning theory and the results of relevant studies. This board game contains a summary, answer booklet, and multiple card game tasks including situations of interpersonal interaction. The participants must discuss, share personal experiences, and find the answer together.
Study NCT05593770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib100-150mg orally twice daily for 14 days or 28 doses. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
Study NCT05593770 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orange film-coated, plain bioconvex tablets orally twice daily for 14 days or 28 doses for fostamatinib. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
Study NCT05620719 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Posttraumatic Headache
Description: CBT for Posttraumatic Headaches consists of 8 sessions of cognitive behavioral therapy that focus on (1) discussions and exercises that increase awareness of what may be related to headaches, (2) relaxation techniques to manage physiological stress, and (3) problem-solving techniques to manage common stressors. Sessions are delivered weekly and can last between 45 to 75 minutes based on clinical content and patient response to the material.
Study NCT05620719 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Participants will continue to engage in medical care as usual for 8 weeks.
Study NCT05620719 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine-based Cognitive Behavioral Therapy (TCBT)
Description: Participants assigned to TCBT will receive 8 sessions of cognitive behavioral therapy using telemedicine rather than face-to face office visits.
Study NCT04974398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab
Description: Arm A: Penpulimab (200 mg, administered on Day 1 of each cycle, Q3W) + cisplatin 80 mg/m2, administered on Day 1 of each cycle, Q3W, up to 6 cycles) + gemcitabine 1000 mg/ m2, administered on Days 1 and 8 of each cycle, Q3W, up to 6 cycles), 3 weeks (21 days) per treatment cycle (Q3W), and then followed by penpulimab monotherapy as maintenance treatment, Q3W.
Study NCT04974398 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Arm B: Placebo (200 mg, administered on Day 1 of each cycle, Q3W) + cisplatin (80 mg/m2, administered on Day 1 of each cycle, Q3W, up to 6 cycles) + gemcitabine (1000 mg/m2, on Days 1 and 8 of each cycle, Q3W, up to 6 cycles), every 3 weeks (21 days) per treatment cycle and then followed by placebo monotherapy as maintenance treatment, Q3W. Subjects in Arm B will have the opportunity to crossover to open-label treatment with penpulimab monotherapy after radiographic disease progression.
Study NCT06642623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enavogliflozin
Description: The dosage and administration method are determined according to the investigator's judgment, considering the drug's approval requirements and the medical condition of the study participants.
Study NCT06642623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin or Empagliflozin
Description: The dosage and administration method are determined according to the investigator's judgment, considering the drug's approval requirements and the medical condition of the study participants.
Study NCT06638801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coach-led caregiver-implemented early literacy and developmental programming
Description: Caregivers will receive training about child brain development in the first 3 years of life. The training will emphasize the areas of spoken words, physical education, pointer-finger concept, focus and label, reading lessons, and mathematics.
Study NCT06638801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reach Out and Read Training
Description: Reach Out and Read parent training
Study NCT06638801 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reach Out and Read Training
Description: Reach Out and Read parent training
Study NCT06639880 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care exercise
Description: the usual care for the lumbar spine which includes TENS, ultrasound, and myofascial release for the lumbar spine in addition to a core program including bridge, half bridge and clam shell exercise
Study NCT06639880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: triple attack protocol
Description: a modified P-A mobilization, manipulation, and stabilization program (Active and passive) for the thoracic spine in addition to the usual care and the core program for the lumbar spine
Study NCT06641453 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GPC3-CART cells
Description: Phase 1: Dose escalation (3+3): Dose 1 (1 × 10\^6 cells/kg) with or without FC regimen, Dose 2 (3 × 10\^6 cells/kg), Dose 3 (6 × 10\^6 cells/kg).~Phase 2: Dose at RP2D.
Study NCT06641453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate for Injection
Description: Administered intravenously at a dose of 20-30 mg/m²/day on days -5, -4, and -3.
Study NCT06641453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide for Injection
Description: Administered intravenously at a dose of 300-500 mg/m²/day on days -5, -4, and -3.